Tags

Type your tag names separated by a space and hit enter

[Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis].
Rinsho Shinkeigaku. 2020 Feb 27; 60(2):117-119.RS

Abstract

The recent development of a cell-based assay that can detect specific autoantibodies revealed the clinical features of diseases associated with the anti-myelin oligodendrocyte glycoprotein (MOG) antibody. The anti-MOG antibody associated diseases may include inflammatory demyelinating central nervous system diseases such as neuromyelitis optica spectrum disorders, optic neuritis, myelitis, atypical multiple sclerosis, and encephalitis. Among them, anti-MOG antibody associated cortical encephalitis may develop seizure as one of the primary symptoms, present unique lateral or bilateral medial frontal cortical lesions on brain MRI FLAIR images. In acute phase, steroid pulse therapy and anti-epileptic drugs are required. In chronic phase, immunosuppressive drugs are often required to prevent relapses.

Links

Publisher Full Text

Authors+Show Affiliations

Fujimori J
Department of Neurology, Tohoku Medical and Pharmaceutical University.

MeSH

AnticonvulsantsAutoantibodiesBrainEncephalitisHumansImmunosuppressive AgentsMagnetic Resonance ImagingMethylprednisoloneMyelin-Oligodendrocyte GlycoproteinPulse Therapy, Drug

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

31956198

Citation

Fujimori, Juichi. "[Anti-myelin Oligodendrocyte Glycoprotein Antibody Associated Encephalitis]." Rinsho Shinkeigaku = Clinical Neurology, vol. 60, no. 2, 2020, pp. 117-119.
Fujimori J. [Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis]. Rinsho Shinkeigaku. 2020;60(2):117-119.
Fujimori, J. (2020). [Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis]. Rinsho Shinkeigaku = Clinical Neurology, 60(2), 117-119. https://doi.org/10.5692/clinicalneurol.cn-001379
Fujimori J. [Anti-myelin Oligodendrocyte Glycoprotein Antibody Associated Encephalitis]. Rinsho Shinkeigaku. 2020 Feb 27;60(2):117-119. PubMed PMID: 31956198.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis]. A1 - Fujimori,Juichi, Y1 - 2020/01/19/ PY - 2020/1/21/pubmed PY - 2020/8/21/medline PY - 2020/1/21/entrez KW - anti-myelin oligodendrocyte glycoprotein antibody KW - cortical encephalitis KW - epilepsy KW - steroid SP - 117 EP - 119 JF - Rinsho shinkeigaku = Clinical neurology JO - Rinsho Shinkeigaku VL - 60 IS - 2 N2 - The recent development of a cell-based assay that can detect specific autoantibodies revealed the clinical features of diseases associated with the anti-myelin oligodendrocyte glycoprotein (MOG) antibody. The anti-MOG antibody associated diseases may include inflammatory demyelinating central nervous system diseases such as neuromyelitis optica spectrum disorders, optic neuritis, myelitis, atypical multiple sclerosis, and encephalitis. Among them, anti-MOG antibody associated cortical encephalitis may develop seizure as one of the primary symptoms, present unique lateral or bilateral medial frontal cortical lesions on brain MRI FLAIR images. In acute phase, steroid pulse therapy and anti-epileptic drugs are required. In chronic phase, immunosuppressive drugs are often required to prevent relapses. SN - 1882-0654 UR - https://www.unboundmedicine.com/medline/citation/31956198/[Anti_myelin_oligodendrocyte_glycoprotein_antibody_associated_encephalitis]_ L2 - https://dx.doi.org/10.5692/clinicalneurol.cn-001379 DB - PRIME DP - Unbound Medicine ER -